

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
10 October 2024 (10.10.2024)



(10) International Publication Number
WO 2024/209363 A1

(51) International Patent Classification:

C07D 231/56 (2006.01) C07D 471/04 (2006.01)
C07D 403/10 (2006.01) A61P 37/00 (2006.01)
C07D 405/04 (2006.01) A61P 29/00 (2006.01)
C07D 409/10 (2006.01) A61P 1/00 (2006.01)
C07D 417/10 (2006.01) A61K 31/416 (2006.01)

(21) International Application Number:

PCT/IB2024/053239

(22) International Filing Date:

03 April 2024 (03.04.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/494,598 06 April 2023 (06.04.2023) US

(71) Applicant: PFIZER INC. [US/US]; 66 Hudson Boulevard East, New York, New York 10001-2192 (US).

(72) Inventors: BHATTACHARYA, Samit Kumar; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). CAMERON, Kimberly O'Keefe; 21 Lake View Heights, Niantic, Connecticut 06357 (US). CONN, Edward Lee; c/o Pfizer Inc., 445 Eastern Point Road, Building 98, Groton, Connecticut 06340 (US). EBNER, David Christopher; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). FERNANDO, Dilinie Prasad-hini; 6 Driftwood Road, Jamaica Plain, Massachusetts 02130 (US). FILIPSKI, Kevin James; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). GERSTENBERGER, Brian Stephen; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). HUH, Chan Woo; c/o Pfizer Inc., 445 Eastern Point Road, Building 98, Groton, Connecticut 06340 (US). KUNG, Daniel Wei-Shung; c/o Pfizer Inc., 445 Eastern Point Road, Building 98, Groton, Connecticut 06340 (US). LEE, Esther Cheng Yin; 16 Furber Lane, Newton, Massachusetts 02459 (US). MATHIOWETZ, Alan Martin; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). MEAR, Sarah Jane; c/o Pfizer Inc., 445 Eastern Point Road, Building 98, Groton, Connecticut 06340

(US). O'BRIEN, Jessica Gloria Katherine; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). SMITH, Aaron Christopher; 17872 West 59th Avenue, Golden, Colorado 80403 (US). TU, Meihua Mike; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US).

(74) Agent: ZIELINSKI, Bryan C.; PFIZER INC., Legal Division, 66 Hudson Boulevard East, 11th Floor, New York, New York 10001-2192 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: SUBSTITUTED INDAZOLE PROPIONIC ACID DERIVATIVE COMPOUNDS AND USES THEREOF AS AMPK ACTIVATORS



(57) Abstract: The invention relates to substituted indazole propionic acid derivatives of formula (I), pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof that can activate adenosine 5'-monophosphate- activated protein kinase (AMPK). The invention further relates to pharmaceutical compositions comprising AMPK-activating substituted indazole propionic acid derivatives of formula (I), pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof and at least one pharmaceutically acceptable excipient, and methods of treating a condition comprising administering AMPK-activating substituted indazole propionic acid derivatives of formula (I), pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof.

WO 2024/209363 A1